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THE present prospective study showed that incidence of
systemic infection in severe burn patients was 30.9%.
Toxic shock and multiple organ failure (MOF) developed
in all patients with uncontrolled systemic infection. Both
morbidity and mortality ofMOF were 76.5%. In the infec-
tion group, plasma TXB. and TXB2/6-keto-PGFI ratio
increased markedly. Their changes were closely correlated
with the clinical course and deterioration of systemic
infection. Circulatory platelet aggregate ratio decreased
significantly, while myocardiac enzyme spectrum greatly
increased. Thrombi were observed in visceral tissues from
patients dying of systemic infection. These suggested
that TXA2/PGL. imbalance promoting microaggregate and
thrombus formation may be one of the pathogenic effects
of toxic shock and MOF in burn patients.
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Introduction
It is well known that systemic infection is one Of
the main causes of multiple organ failure (MOF)
and death in severe burn patients. However, most
of the previous studies were designed to define
how systemic infection occurs, and the mechanisms
of the pathophysiological alterations induced by
burn systemic infection were seldom investigated.
It has been reported
2-4 that thromboxane
A2(WXae)/prostacyclin in (POI2) imbalance played
important roles in the pathophysiological changes
in endotoxic animals. Treatment with PGI2
improved survival of lethal endotoxaemia in dogs.
Nevertheless, no reports concerning their roles in
the pathophysiological alterations of burn systemic
infection have been found. In the present study, we
investigated the changes of plasma levels of TXA2
and PGI2 in burn systemic infection patients in
order to define the role of TXA2 and PGI2
imbalance in the pathogenesis of pathophysiological
alterations of systemic infection in severe burns.
Materials and Methods
Fifty-five patients admitted to our institute from
February 1987 to October 1988 were divided into
infection group and non-infection group according
to patients complicated with or without systemic
infection within 7 days post-burn (PB). In the
infection group, there were 17 patients, eleven
males and six females. Average patient age was
29.0 __+ 3.3 (17-53) years and total burn surface
area (TBSA) was 82.5 4.1 (45-98) %. Of the 17
cases, eleven developed septicaemia and six wound
sepsis. The non-infection group included 38
patients, 25 males and 13 females, with an average
age of 28.6 + 3.1 (16-58) years and an average
TBSA of 51.6-t-4.1 (30-85) %. The time for
occurrence of systemic infection was 1 post-burn
day (PBD) in two cases; and 3-7 PBD in 15 cases
(88.2%). Among the eleven septicaemia cases, there
were 17 positive blood culture with ten strains of
different bacteria. Pseudomonas aeruginosa was dis-
covered in seven of the 17 (41.2%); both
staphylococci and serratia in two (11.8%). Two
cases were infected with two, and three cases with
three species of bacteria. Five patients developed
mixed blood infection with 5 PBD, two cases with
two strains, three with three strains of different
bacteria.
All patients were given conventional treatment
after admission. Blood samples were collected and
studied at 0.5, 1, 2, 3, 5 and 7 PBD, respectively.
Plasma levels of TXB2, the stable product of
TXA., and 6-keto-PGFl, the stable degradation
product of PGI2, were assayed with a radio-
immunoassay (RIA) technique. RIA kits were
supplied by the General Hospital of PLA, Beijing.
Blood samples were drawn with siliconized syringes
containing heparin and indomethacin, and then
collected in pyrogen-free siliconized glass tubes.
Specimens were spun for 15 min at 1500 x g at
4C and the plasma fraction was extracted twice
with ethyl acetate. The extracted supernatant, after
drying in a vacuum desiccator, were available for
TXB2 and 6-keto-PGFl determination. RIA was
then performed with commercially available stan-
dards, trace compounds, and antisera, according to
the RIA procedures for TXB26 and the description
of 6-keto-PGFl RIA kits of the General Hospital
of PLA, Beijing. All assay points were run in
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duplicate. The antibodies used to measure TXB.
and 6-keto-PGFl cross-react less than 0.42%
to 0.0025% with other prostaglandins. Circulatory
platelet aggregate ratio (CPAR) was determined
with the method of Wu and Hoak.
7 The
EDTA/formalin solution and EDTA solution were
prepared as described by Wu and Hoak. 7 Venous
blood (1 ml) was drawn with a siliconized syringe
and added into two siliconized glass tubes (0.5 ml
for each tube), one containing 2 ml of buffered
EDTA/formalin solution and the other buffered
EDTA solution only. After thorough mixing, the
samples were kept at room temperature (20C to
25C) for 15 min and then centrifuged at 150 g
for 8 min to obtain platelet rich plasma (PRP).
Platelet counts on both PRP samples were
determined with light microscopy. Values of
circulatory platelet aggregate ratio (CPAR) were
obtained by dividing platelet count in EDTA/-
formalin PRP by platelet count in EDTA PRP. The
myocardial enzyme spectrum (creatinine phospho-
kinase, CPK; lactate dehydrogenase, LDH; and
glutamine oxaloacetic acid transaminase, GOT) was
measured by a routine method. Pathomorphologi-
cal observations of myocardiac, lung, liver and renal
tissues immediately taken from seven MOF patients
of the infection group who died within 7 PBD were
carried out with light microscopy.
Statistical analysis" All results were expressed as mean
values -t-S.E.M. Statistical analysis was performed
with analysis of variance.
Results
Clinical manifestations: All patients in the infection
group showed obvious toxic symptoms such as
high or low body temperature, altered mental
status, tachypnoea, tachycardia, ileus, leukocytosis
with left shift or leukopenia during the period of
infection. With administration of effective antibio-
tics in four cases (three with septicaemia and one
with wound sepsis) the inrection was controlled 2
to 3 days post-infection. In the remaining 13
patients toxic shock or/and multiple organ failure
(MOF) emerged subsequently. All the 13 patients
succumbed to toxic shock or/and MOF, and ten
(76.9%) of them died within 7 PBD. Both the
incidence of MOF and mortality of burn systemic
infection in this study were 76.5%.
Plasma levels ofTXBe, 6-keto-Pgtv, (#k-P) and TXBe/6-
k-P ratio: The plasma levels ofTXB2 in the infection
group increased significantly by 12 h post-burn but
then gradually decreased during the next 1.5 days
(by day 2). They markedly increased again during
3 to 7 PBD. There was no significant difference in
the plasma levels of 6-k-P between the two groups.
Plasma levels of the TXBe/6-k-P ratio in the
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FIG. 1. Dynamic changes in plasma levels of TXB2.6-keto-PGFl= (6-k- P)
and TXB2/6-k-P ratio in infection (--) and non-infection (-.-) groups
of severe burn patients. *p < 0.05, ***p < 0.01.
infection group, elevated initially at 12 h and during
3 to 7 PBD, showed significant differences com-
pared with those found in the non-infection group
(Fig. 1).
The circulatory platelet aggregate ratio (CPAR)
in the infection group, as shown in Fig. 2, showed
no significant difference compared with that in the
non-infection group within 1 PBD. After PBD 2
its level remained low in the infection group, but
gradually recovered in the non-infection group.
The difference between the two groups became
significant.
Levels of plasma TXB2 and CPAR in 13 MOF
patients of the infection group are shown in Table
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FIG. 2. Changes of circulatory platelet aggregate ratio (CPAR) in infection
(--) and non-infection (-.-) groups of severe burn patients,
**p < 0.01.
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Table 1. Results of TXB2 and CPAR in 13 MOF patients of the
infection group mean _+ S.E.M.
Before During During MOF
infection infection
TXB2 2007.1 __+ 269.6 2715.8 __+ 361.3 3443.5 __+ 266.5
(pg/ml)
CPAR 0.62 _+ 0.05 0.40 + 0.04 0.32 + 0.04
1. TXB2 was higher during the MOF stage than
during the infection. In contrast, levels of CPAR
further declined when MOF occurred. The level of
CPK increased in both groups post-burn. However,
in the non-infection group it remained significantly
higher and manifested a greater tendency to increase
than in the non-infection patients. Levels of LDH
and GOT showed similar changes (Fig. 3).
Pathomorphologically, cloudy swelling and frag-
mentation of myocardial fibres, interstitial oedema
and haemorrhage in myocardial tissues were
observed. Congestion, oedema, haemorrhage and
thrombosis were the main pathomorphological
alterations found in the lung tissues. The common
findings in renal tissues included ischaemia,
swelling, collapse or ischaemic and necrotic changes
in the glomeruli, dilatation of tubules containing
heme or hyaline casts and thrombosis in the
microvasculature. Cloudy swelling, fatty meta-
morphosis and necrosis were demonstrated in
hepatic tissues.
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FIG. 3. Changes in levels of myocardial enzyme spectrum (CPK, LDH and
GOT) in infection (--) and non-infection (-.-) patients with severe
burns. *p < 0.05, **p < 0.01.
Discussion
The findings of this present prospective clinical
study revealed that the incidence of systemic
infection in severe burn patients was 30.9%. Except
for four cases, which were controlled by administer-
ing antibiotics, 13 of the 17 patients in the infection
group developed toxic shock and MOF, and
subsequently died of MOF. As is well known,
circulatory microaggregate formation is one of the
major pathogenic features of toxic shock and
MOF. 8’9 Wang and his colleagues
1 found that
during the early stage of endotoxic shock, there
were microaggregates mainly consisting of platelets
in microvasculatures of lung, liver and renal tissues,
and the microaggregates, as stated by the authors,
played an important role in the genesis of visceral
dysfunctions. During the late stage of endotoxic
shock, the microaggregates gradually evolved into
disseminated intravascular coagulation, which was
one of the main causes of death due to deterioration
of shock and/or MOF caused by systemic infection.
However, the pathogenesis of shock and MOF
caused by systemic infection in burn patients is not
yet clarified.
It is known that TXA2 is the most potent platelet
aggregator known and an extremely strong
vasoconstrictor. Conversely, PGI2 is a strong
vasodilator and antiplatelet aggregator. The precise
balance of these two mediators is an important
determinant of the levels of vascular tone, platelet
function and many other cellular homeostatic
functions.4 Many previous studies have demon-
strated that the imbalance ofTXA2 and PGI2 played
important roles in the pathophysiological al-
terations of toxic shock such as pulmonary
hypertension, cardiac reduction and hypotension in
non-burnt patients.4’11’12 Treatment with a TXA2
inhibitor showed beneficial eEects in endotoxic
shock in rats.
13 The results of this study
demonstrated that plasma levels of TXA2 and the
TXAe/PGI2 ratio in the infection group were
significantly higher than those in the non-infection
group. Further analysis of their dynamic changes
revealed that the changes of plasma TXAe/PGI2
ratio within 7 PBD exhibited two peaks of interest.
The first peak occurred within 1 PBD and the
second during 3 to 7 PBD. As reported before,
4
the first peak might be correlated with the genesis
and development of burn shock. Combining the
time at which the TXAe/PGI2 ratio altered with the
clinical manifestations and the results of blood
bacterial culture of the 17 patients with infection,
it was found that 15 of the 17 infection cases
developed systemic infection during 3 to 7 PBD, of
which 13 cases died of toxic shock and/or MOF
during days 3 to 7 of the post-burn period. Our
14 15 previous studies’ confirmed that TXA2 pro-
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moted microaggregate formation and played
important roles in the genesis and development of
post-burn shock and MOF. The present study also
demonstrated that the level of CPRA was lower
during infection than before emergence of infec-
tion, and further decreased when MOF occurred.
In contrast, plasma levels of TXA2 in MOF cases
in the infection group increased further. These
results substantiated that the second peak of the
TXAe/PGI2 ratio coincided with the development
of toxic shock and/or MOF, and the deterioration
of the general conditions of the patients with
infection. Thus it is proposed that the imbalance
between TXA2 and PGI2 may be one of the factors
of the pathophysiological changes (shock and
MOF) in severe burn patients complicated with
systemic infection.
According to the findings of this present study,
the promoting action of microaggregates and
thrombi by imbalance of TXA2 and PGI2 was the
important pathogenesis of pathophysiological al-
terations in burn infection patients. As stated above,
microaggregate formation is one of the important
factors leading to toxic shock and/or MOF in the
infected victims in non-burn cases. We also
observed microaggregates and thrombi in burn
patients with MOF. Microaggregates were also
observed in the visceral microvasculatures of
patients who died of toxic shock.
16 It has been
confirmed that TXA2 is a potent platelet proag-
gregator.
17 The results of this study showed that
circulatory platelet aggregate ratio (CPAR) was
significantly decreased within 7 PBD and showed
further decreases during 5 to 7 PBD, suggesting the
increased formation of circulatory platelet microag-
gregates in burn patients suffering from systemic
infection. Furthermore, pathomorphological ob-
servations revealed thrombi in the microvascu-
latures of the main visceral tissues from patients of
the infection group in this study. It is well known
that microaggregates and thrombi can cause
haemorrheological and haemodynamic disturbances
leading to tissue and visceral damage via machanical
obstruction of microvasculatures and release of
chemical mediators.
18 Therefore, the results of this
study suggested that microaggregates and thrombi
may also be the basis of the pathophysiological
changes initiated by systemic infection in severe
burn patients. Levels ofTXA2 and the TXA2/PGI2
ratio in the infection group of this study markedly
increased and the second peak occurred before the
level of CPAR further declined suggesting that
imbalance of TXA2 and PGI2 played an important
role in the formation of microaggregates and
thrombi in the infection group. Levels of CPK,
LDH and GOT in the infection group increased
continually, reflecting tissue and visceral ischaemia
and damage due to haemodynamical and hae-
morrheological disturbances, and augmentation of
microvascular permeability induced by microag-
gregates and thrombi promoted by increased
TXAe/PGI2 ratio. Therefore, this study sub-
stantiated that the imbalance between TXA2 and
PGI2 may be one of the factors leading to the
pathophysiological alterations of systemic infection
in patients with severe burns.
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